Ranking tables

Pharma/Life Sciences: Corporate | Europe

France

The below Pharma/Life Sciences: Corporate rankings table provides market-leading insights on the top ranked lawyers and law firms whose advice and legal services can be purchased in France. The rankings are the result of extensive research by our internal research team, who conduct interviews with in-house counsel, other third-party experts and private practice lawyers who have worked alongside them. Use our table and ranking system to identify the most suited provider of legal services for you.

All Lawyers profiles

1
Band 1
  1. Alain Decombe
    1
    Alain Decombe
    Dechert LLP
    Dechert LLP | Pharma/Life Sciences: Corporate
    2024 | Band 1 | 18 Years Ranked
    Alain Decombe maintains an eminent reputation for his advice on corporate transactions in the life sciences sector. He is adept at assisting with cross-border mandates.
  2. Emmanuelle Trombe
    1
    Emmanuelle Trombe
    McDermott Will & Emery
    McDermott Will & Emery | Pharma/Life Sciences: Corporate
    2024 | Band 1 | 17 Years Ranked
    Emmanuelle Trombe is widely recognised as a leading corporate practitioner in the pharmaceutical and life sciences sectors, with outstanding expertise in acquisitions, financing rounds and licensing agreements.
  3. Jean-Marc Grosperrin
    1
    Jean-Marc Grosperrin
    Dentons
    Dentons | Pharma/Life Sciences: Corporate
    2024 | Band 1 | 11 Years Ranked
    "Jean-Marc is an exceptional lawyer with strong business acumen. He is able to explain any complex topics in a very pedagogical way, he is very pragmatic. It is a pleasure to work with him especially on sensitive topics."
2
Band 2
  1. Emmanuelle Porte
    2
    Emmanuelle Porte
    Bird & Bird
    Bird & Bird | Pharma/Life Sciences: Corporate
    2024 | Band 2 | 4 Years Ranked
    Emmanuelle Porte of Bird & Bird handles a range of corporate matters in the pharmaceutical sector, including acquisitions and fundraisings.
  2. Gilles Bigot
    2
    Gilles Bigot
    Winston & Strawn
    Winston & Strawn | Pharma/Life Sciences: Corporate
    2024 | Band 2 | 8 Years Ranked
    Gilles Bigot of Winston & Strawn boasts longstanding experience advising investment funds and corporates on transactional matters, including primary LBOs.
    Key sectors
    Health and Life Sciences
  3. Renaud Bonnet
    2
    Renaud Bonnet
    Jones Day
    Jones Day | Pharma/Life Sciences: Corporate
    2024 | Band 2 | 18 Years Ranked
    Renaud Bonnet is highly recognised for assisting technology and life sciences companies with a range of corporate transactions, including financing rounds and initial public offerings.
3
Band 3
  1. Anne-Charlotte Rivière
    3
    Anne-Charlotte Rivière
    Goodwin
    Goodwin | Pharma/Life Sciences: Corporate
    2024 | Band 3 | 7 Years Ranked
    Anne-Charlotte Rivière enters the rankings this year on the back of excellent market recognition. She advises clients on corporate matters in the life science space, offering notable experience in venture capital and M&A transactions.
  2. Anthony Paronneau
    3
    Anthony Paronneau
    McDermott Will & Emery
    McDermott Will & Emery | Pharma/Life Sciences: Corporate
    2024 | Band 3 | 3 Years Ranked
    "I am very lucky to have Anthony involved in this process, he is a calming force to have around, he allows the discussions to move forwards, keeps calm in all situations and he is a key asset for us."
  3. Sonia de Kondserovsky
    3
    Sonia de Kondserovsky
    DLA Piper France LLP
    DLA Piper France LLP | Pharma/Life Sciences: Corporate
    2024 | Band 3 | 2 Years Ranked
    Sonia de Kondserovsky of DLA Piper LLP assists pharmaceutical companies with cross-border acquisitions and investments.
U
Up and Coming
  1. Anne-France Moreau
    U
    Anne-France Moreau
    McDermott Will & Emery
    McDermott Will & Emery | Pharma/Life Sciences: Corporate
    2024 | Up and Coming | 1 Years Ranked
    Up-and-coming partner Anne-France Moreau joins the table thanks to her experience handling M&A mandates in the pharma sector, including private equity transactions.